New breast cancer drug

A new breast cancer drug Avastin, has been licensed in UK.
The new drug – Avastin is designed to be used in tandem with another chemotherapy agent, paclitaxel.
Avastin, has previously been used to treat bowel cancer.
In trials, breast cancer patients who took Avastin and paclitaxel went an average of 13 months without their cancer growing, compared with an average of 6.7 months for patients who took paclitaxel alone.